Solna, Stockholm Region, Sweden – May 6, 2026 – Cell4Cure AB, a biotechnology company pioneering immune tolerance therapies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,852,706. The patent covers Cell4Cure’s proprietary method for generating autologous tolerogenic dendritic cells (tolDCs). Notably, the grant includes a Patent Term Adjustment of 817 days, extending the patent’s protection well into 2043.

Solna, Stockholm Region, Sweden – March 9, 2026 – Swedish biotech company Cell4Cure AB,
specializing in immune tolerance therapies via autologous tolerogenic dendritic cells (tolDCs),
today announced the formal grant of a key patent in Japan. This achievement reinforces
Cell4Cure’s intellectual property position and extends the company’s patent protection to include
the Japanese market.

Solna, Stockholm Region, Sweden – July 11, 2025 – Swedish biotech company Cell4Cure AB, which is advancing a breakthrough platform in immune tolerance therapies using autologous tolerogenic dendritic cells (tolDCs), today announced the successful grant of key patent in China. This significant achievement further solidifies Cell4Cure's intellectual property position and expands its global footprint in the rapidly growing Chinese market.

​Solna, Stockholm Region, Sweden – June 12, 2025 – Swedish biotech company Cell4Cure AB, an innovator in immune tolerance therapies utilizing autologous tolerogenic dendritic cells (tolDCs), today announced its digital participation in the 4th Nordic Health Summit Japan. The summit is scheduled for June 27th, 2025, in Central Tokyo.

Solna, Stockholm Region, Sweden – June 2, 2025 – Swedish biotech company Cell4Cure AB, advancing a breakthrough platform in immune tolerance therapies using autologous tolerogenic dendritic cells (tolDCs), will participate in the BIO International Convention in Boston, June 16-19.

Solna, Sweden, 4 March 2025, Cell4Cure AB – a Swedish, privately held biotech company, pioneering the development of immune tolerance therapies – today announced its strategic partnership with Bartlett Hill Partners LLC, a leading advanced therapies consulting group to lead its Business Development initiatives in North America.

Solna, Sweden, 26 February 2025, – Cell4Cure AB, a privately held Swedish biotech company at the forefront of immune tolerance therapies, today announced that its proprietary technology platform was a key component of the PhD thesis successfully defended by Dr. Gillian Dao Nyesiga on February 21 at Malmö University

Solna, Sweden, 13 January 2025, Cell4Cure AB – a Swedish, privately held biotech company, founded in 2023, pioneering immune tolerance therapies – today announced that they will participate at Arab Health Exhibition and Congress taking place in Dubai 27-30 January.

​

Cell4Cure announced today that they have appointed Dr Rolf Ljung, Professor of Pediatrics at Lund University, Sweden as senior advisor for its first clinical program.

Cell4Cure announced today that they have appointed Dr Jolanda de Vries as advisor to support the continued development of the company’s dendritic cell therapy promoting antigen-specific tolerance.

Today, Cell4Cure announced that they have joined the national trade organization for life sciences in Sweden, SwedenBIO.

Today, Cell4Cure proudly announce that their tolerogenic dendritic cell therapy for Hemophilia A (FVIII) was presented at Biotech Showcase™ during the JP Morgan 42nd Annual Healthcare Conference in San Francisco during January 2024, by its US-based collaborator RND Pharmaceuticals, through Dr Ramon Mohanlal, CEO RND Pharmaceuticals Inc.

Today, Cell4Cure proudly announce the appointment of Dr. Leif Salford, former Professor of Neurosurgery at Lund University as our Senior Advisor

Today, Cell4Cure announced that the board has appointed Christina Herder as the CEO for the newly founded company.

Today we announce that Cell4Cure have joined the non profit organization ATMP Sweden.

Today, Cell4Cure announced that we have appointed Sharon Longhurst, Advanced Biologics Consulting, as its Chemistry, Manufacturing and Controls (CMC) expert.

Cell4Cure today announced that we have won the formal bidding process to acquire the technology platform in from Idogen AB.